Visvanathan, Sudha https://orcid.org/0000-0002-1170-9272
Daniluk, Stefan
Ptaszyński, Rafał
Müller-Ladner, Ulf
Ramanujam, Meera
Rosenstock, Bernd
Eleftheraki, Anastasia G
Vinisko, Richard
Petříková, Alena
Kellner, Herbert
Dokoupilova, Eva
Kwiatkowska, Brygida
Alten, Rieke
Schwabe, Christian
Baum, Patrick
Joseph, David
Fine, Jay S
Padula, Steven J
Steffgen, Jürgen
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
https://doi.org/10.1136/annrheumdis-2018-214729
Funding for this research was provided by:
Boehringer Ingelheim
This article is maintained by: Elsevier
Article Title: Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2018-214729
Content Type: article
Copyright: Copyright © 2019 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.